More tools:Markets·Screener·Research·Chat

Biogen Inc. Common Stock (BIIB) Financial Statements

Biogen Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001S67826
XNAS · usd
212.50▼ 8.33 (-3.77%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close220.83
Day's Range210.54 – 217.28
52-Week Range135.39 – 225.80
Volume617.4K
Avg Volume850.9K
Share Statistics
Shares Outstanding
Employees7,500
ExchangeXNAS
Listed1991-09-17
Share count as of July 27, 2026
Loading Income Statement…
Key questions about Biogen Inc. Common Stock (BIIB)
What is Biogen Inc. Common Stock's Market Cap?
Biogen Inc. Common Stock's Market Cap is $31.4B, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's Enterprise Value?
Biogen Inc. Common Stock's Enterprise Value is $37.4B, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's Trailing P/E?
Biogen Inc. Common Stock's Trailing P/E is 37.6×, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's Price / Sales?
Biogen Inc. Common Stock's Price / Sales is 3.1×, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's EV / Revenue?
Biogen Inc. Common Stock's EV / Revenue is 3.7×, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's EV / EBITDA?
Biogen Inc. Common Stock's EV / EBITDA is 18.1×, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's Revenue (TTM)?
Biogen Inc. Common Stock's Revenue (TTM) is $10.0B, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's Net Income (TTM)?
Biogen Inc. Common Stock's Net Income (TTM) is $834.6M, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's EBITDA?
Biogen Inc. Common Stock's EBITDA is $2.1B, based on as-reported figures from SEC (XBRL) filings.
What is Biogen Inc. Common Stock's Diluted EPS (TTM)?
Biogen Inc. Common Stock's Diluted EPS (TTM) is 5.65, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Total revenue
YoY growth+3.4%+1.9%-7.1%+2.8%
Cost and expenses:
Cost of sales, excluding amortization and impairment of acquired intangible assets
Research and development
Acquired in-process research and development, upfront and milestone expense
Selling, general and administrative
Amortization and impairment of acquired intangible assets
Collaboration profit sharing/(loss reimbursement)
(Gain) loss on fair value remeasurement of contingent consideration
Restructuring charges
Other (income) expense, net
Total cost and expense
% of revenue95.2%84.8%102.5%78.0%
Income before income tax (benefit) expense
Income tax (benefit) expense
Net income attributable to Biogen Inc.
% of revenue3.6%12.9%-2.1%18.4%
Basic earnings per share attributable to Biogen Inc. (in USD per share)
Diluted earnings per share attributable to Biogen Inc. (in USD per share)